ストックスクリーナーアプリを入手
1.20
0.00%
0.00
前日終値:
$1.20
開ける：
$1.2
24時間の取引高:
14,094
Relative Volume:
0.08
時価総額：
$2.46M
収益：
$72,100
当期純損益:
$-4.84M
株価収益率:
-0.1609
EPS:
-7.4566
ネットキャッシュフロー:
$-3.84M
1週間 パフォーマンス:
-17.24%
1か月 パフォーマンス:
-38.14%
6か月 パフォーマンス:
-80.46%
1年 パフォーマンス:
-87.88%
1日の値動き範囲:
$1.15
$1.235
1週間の範囲:
$1.10
$1.49
52週間の値動き範囲:
$1.10
$10.43
Silo Pharma Inc Stock (SILO) Company Profile
Compare SILO vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SILO
Silo Pharma Inc
|
1.20 | 2.46M | 72,100 | -4.84M | -3.84M | -7.4566 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silo Pharma Inc (SILO) 最新ニュース
Silo Pharma Acquires IP Assets in Strategic Agreement - The Globe and Mail
A warrant for up to 300,000 shares is Silo Pharma (SILO)'s payment for software assets. - Stock Titan
NVIDIA models join QwikAgents, which adds a second software option for AI assistants. - Stock Titan
Why Is Silo Pharma (NASDAQ:SILO) Moving Into Focus? - Kalkine Media
Silo Pharma Inc (NASDAQ: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - kalkine.com.au
Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum - marketscreener.com
Silo Pharma to Present at IPAC-RS 2026 Nasal Innovation Forum, Highlighting Progress of PTSD Candidate SPC-15 - citybuzz -
Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development - Quiver Quantitative
A nasal PTSD treatment met specs for nine months - Stock Titan
Silo Pharma Stock Price Forecast. Should You Buy SILO? - StockInvest.us
Silo Pharma Inc (NYSE: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - Kalkine
Silo Pharma Inc (SILO) Peer Comparison – Compare with Others - Value Research
Silo Pharma Inc (SILO) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Silo Pharma Acquires Digital Assets via Stock Issuance - The Globe and Mail
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com South Africa
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com Nigeria
Silo Pharma Acquires Digital Assets via Stock Issuance - TipRanks
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com Canada
Form 8K Silo Pharma Inc For: 19 August - Investing.com India
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com UK
Silo Pharma Acquires Software and IP From Parkview Consulting for 165,000 Shares - TradingView
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting - TradingView
Silo Pharma (SILO) grants 165K locked-up shares in tech deal - Stock Titan
Silo PharmaEnters Asset Purchase Agreement - Moomoo
SILO 8-K & SEC Filings - Yahoo Finance Australia
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com Canada
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com Australia
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - manilatimes.net
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com India
Silo Pharma Receives Notice of Allowance for Canadian Patent Application Covering Lead Asset Spc-15 Targeting Ptsd and Other Stress-Induced Psychiatric Disorders - marketscreener.com
Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current UpdateSuperTrend - Vinanet
Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current UpdateCommon Gap - dars.gov.et
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - GlobeNewswire
Silo Pharma Shareholders Approve Major Share Authorization Expansion - TipRanks
Silo Pharma (SILO) holders approve lifting share cap from 6.7M - Stock Titan
Silo Pharma (SILO) Slips 0.62% to $3.20 as Shares Consolidate Between Key Technical LevelsStock Picks - Vinanet
Silo Pharma (SILO) trims cash burn, mitigates going-concern risk in Q2 2026 - Stock Titan
Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Silo Pharma (SILO) investor group discloses 9.99% warrant-based ownership cap - Stock Titan
Wondering what's happening in today's pre-market session? - ChartMill
Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Granted European Patent Covering Novel PTSD Therapy - The Manila Times
Silo Pharma receives European patent for SPC-15 PTSD treatment - Investing.com India
Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com - Investing.com Canada
Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy - Quiver Quantitative
Silo Pharma Granted European Patent Covering Novel PTSD Therapy - GlobeNewswire
SILO Q4 2023 Earnings: EPS Misses Estimates, Stock Gains 1.2% Despite No RevenueEarnings Beat Streak - dars.gov.et
SILO Q4 2023 Earnings: Wider-than-Expected Loss of -$5.40 per Share Highlights Heavy Pre-Revenue InvestmentTax Rate Impact - vinanet.vn
Silo Pharma Inc (SILO) Stock News Today - TradingKey
SILO Forecast & Price Target - TradingKey
Silo Pharma Inc (SILO) 財務データ
収益
当期純利益
現金流量
EPS
Silo Pharma Inc (SILO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
1.35%
大文字化:
|
ボリューム (24 時間):